Deep dive into achieving the therapeutic target: results from a prospective, 6‑month, observational study nested in routine rheumatoid arthritis care.


Journal

Polish archives of internal medicine
ISSN: 1897-9483
Titre abrégé: Pol Arch Intern Med
Pays: Poland
ID NLM: 101700960

Informations de publication

Date de publication:
26 09 2022
Historique:
pubmed: 15 4 2022
medline: 28 9 2022
entrez: 14 4 2022
Statut: ppublish

Résumé

Achieving remission or lowdisease activity (LDA) is an integral principle of treat‑to‑target (T2T) strategy in rheumatoid arthritis (RA). Prior studies have reported that achieving T2T therapeutic goals may be realistic only for a fraction of patients. Prospective, real‑world data on achieving target disease control in ambulatory care populations are limited for Central and Eastern European countries. The aim of the study was to analyze the efficacy of treatment and determine simple predictors of achieving T2T therapy goals in daily RA practice. This multicenter, 6‑month study evaluated therapy outcomes and clinical characteristics of 791 consecutive RA outpatients, meeting the preset criteria of inadequate disease control. Only 9% of RA patients achieved remission or LAD after 3 months and 35% after 6 months. Achieving treatment targets after 6 months was associated with lower rates of pain, disability, presenteeism and absenteeism, which reflected improved quality of life. Provider views on adherence appeared discordant with patient claims, and did not predict target achievement. Never smoking, lower body mass index, and lower prednisone dose (<7.5 mg daily) were independently associated with a higher likelihood of achieving T2T therapeutic goals after 6 months. A combination of clinical characteristics and provider treatment decisions shapes the "profile" of a patient failing to achieve T2T goals. Low‑dose steroid equivalent, never smoking, and lower body mass index appear as individual characteristics independently associated with achieving LDA / remission at 3 and 6 months.

Identifiants

pubmed: 35420283
doi: 10.20452/pamw.16244
pii:
doi:

Substances chimiques

Antirheumatic Agents 0
Prednisone VB0R961HZT

Types de publication

Journal Article Multicenter Study Observational Study

Langues

eng

Sous-ensembles de citation

IM

Commentaires et corrections

Type : CommentIn

Auteurs

Bogdan Batko (B)

Department of Rheumatology and Immunology, Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski University, Kraków, Poland. bpbatko@gmail.com

Sławomir Jeka (S)

Clinic and Department of Rheumatology and Connective Tissue Diseases, University Hospital No. 2, Collegium Medicum, Nicolaus Copernicus University in Torun, Toruń, Poland

Piotr Wiland (P)

Department of Rheumatology and Internal Medicine, Wroclaw Medical University, Wrocław, Poland

Marek Brzosko (M)

Department of Rheumatology, Internal Diseases, Geriatrics and Clinical Immunology, Pomeranian Medical University in Szczecin, Szczecin, Poland

Włodzimierz Samborski (W)

Department of Rheumatology and Rehabilitation, Poznan University of Medical Sciences, Poznań, Poland

Marcin Stajszczyk (M)

Silesian Rheumatology Center, Rheumatology and Autoimmune Diseases Department, Ustroń, Poland

Jerzy Chudek (J)

Department of Internal Diseases and Oncological Chemotherapy, Faculty of Medical Sciences in Katowice, Medical University of Silesia in Katowice, Katowice, Poland

Zbigniew Żuber (Z)

Department of Pediatrics, Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski Kraków University, Kraków, Poland

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH